Edition:
United States

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

3.42USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$3.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
656,775
52-wk High
$27.93
52-wk Low
$1.02

Select another date:

Wed, Feb 14 2018

BRIEF-Axovant Sciences Initiated Reduction In Its Workforce

* AXOVANT SCIENCES LTD - ‍ ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING

UPDATE 2-Axovant Sciences CEO David Hung resigns, shares tumble

* Axovant shares fall 20 percent to record low (Adds quotes from incoming CEO, Roivant founder, background on David Hung; updates stock price)

Drug developer Axovant's CEO, COO step down

Feb 12 Axovant Sciences Ltd on Monday said Chief Executive Officer David Hung had resigned, nearly a year after his appointment.

UPDATE 2-Axovant shares plunge after key dementia drug program scrapped

* Shares down 50 pct (Updates shares, adds background on disease space, company's comments on second experimental drug)

BUZZ-Axovant Sciences: Slumps as key drug program scrapped

** Drug developer's shares plunge 47.1 pct to $2.84 premarket - stock set to open at record low

Axovant shares plunge after key drug program scrapped

Axovant Sciences Ltd's shares fell nearly 50 percent on Monday after the company scrapped its intepirdine program following the failure of its lead experimental treatment in a mid-stage study on patients suffering from a type of dementia.

Axovant to scrap intepirdine program after dementia trial fails

Jan 8 Axovant Sciences Ltd said on Monday it would discontinue its intepirdine program after the experimental treatment failed in a mid-stage study on patients suffering from a type of dementia.

BRIEF-Axovant Announces Negative Results For Intepirdine In Phase 2B Headway, Pilot Phase 2 Gait, Balance Studies

* AXOVANT ANNOUNCES NEGATIVE RESULTS FOR INTEPIRDINE IN PHASE 2B HEADWAY AND PILOT PHASE 2 GAIT AND BALANCE STUDIES; POSITIVE TRENDS IN EFFICACY SEEN IN PILOT PHASE 2 NELOTANSERIN STUDY

Select another date: